Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients

Yann Vano(Délégation Paris 5), Réza Elaidi(Hôpital Européen Georges-Pompidou), Constance Thibault(Délégation Paris 5), Stéphane Oudard(Délégation Paris 5), Florian Scotté(University of Derby), Haïl Aboudagga(Délégation Paris 5), Marie-Agnès By(Centre Hospitalier Universitaire de Tours), Pauline Tétu(Inserm)

PLoS ONE

April 6, 2018

10.1371/journal.pone.0195042

Cited by 112

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2021|645

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

|Nature|2021|603

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2021|411

Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up

|Annals of Oncology|2020|319